Introduction: Atrial fibrillation (AF) is increasing in prevalence and is associated with
significant morbidity and mortality. The optimal diagnostic and treatment strategies for AF are …

Venous thromboembolism (VTE) is associated with high recurrence, mortality, and cost
burden. Direct oral anticoagulants (DOACs) are currently used for VTE treatment, and they …

Non-vitamin K antagonist oral anticoagulants (NOACs) represent a paradigm shift in the
treatment of non-valvular atrial fibrillation (AF) with major practice guidelines around the …

Background: Venous thromboembolism (VTE) is a common disease in Latin American
settings. Implementing international guidelines in Latin American settings requires …

OBJECTIVE: Non-valvular atrial fibrillation (NVAF) is a common manifestation of cardiac
arrhythmia, whose significance is heightened in the context of an aging global population …

Direct oral anticoagulants (DOACs) carry many advantages over warfarin and are now
considered first line or an alternative for mnay thromboembolic disorders. With the …

Atrial fibrillation (AF) is associated with significant risk of stroke and other thromboembolic
events, which can be effectively prevented using oral anticoagulation (OAC) with either …

BACKGROUND: Direct oral anticoagulants (DOACs) are an alternative to warfarin for
treatment of atrial fibrillation (AF). Evidence demonstrating the efficacy and safety of DOACs …

Introduction and objectives To assess the cost-effectiveness of edoxaban vs acenocoumarol
in the prevention of stroke and systemic embolism in patients with nonvalvular atrial …

Objective Prevention of recurrent stroke in patients with embolic stroke of undetermined
source (ESUS) is challenging. The advent of safer anticoagulation in the form of direct oral …